ZETIA
Total Payments
$932,310
Transactions
74
Doctors
4
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $108,453 | 8 | 0 |
| 2021 | $16,471 | 1 | 0 |
| 2020 | $104,888 | 2 | 0 |
| 2019 | $306,887 | 14 | 0 |
| 2018 | $196,804 | 26 | 0 |
| 2017 | $198,806 | 23 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $932,264 | 70 | 100.0% |
| Food and Beverage | $45.69 | 4 | 0.0% |
Payments by Type
Research
$932,264
70 transactions
General
$45.69
4 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Treatment of unfavorable bleeding patterns in contraceptive implant users | Merck Sharp & Dohme Corporation | $326,714 | 0 |
| ISCHEMIA International Study of Comparative Health Effectiveness with Medical and Invasive Approaches | Merck Sharp & Dohme Corporation | $128,308 | 0 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 compared with Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia | Merck Sharp & Dohme LLC | $108,453 | 0 |
| Using focus group to explore cultural acceptability of long acting contraception in a diverse, urban population | Merck Sharp & Dohme Corporation | $95,486 | 0 |
| Assessment of cultural acceptability of long acting contraception in a diverse, urban population of young women | Merck Sharp & Dohme Corporation | $82,471 | 0 |
| Role of Netrin-1 in Blunting the Effectiveness of Lipid Lowering to Regress Atherosclerosis in Chronic Kidney Disease Using Novel Mouse Models | Merck Sharp & Dohme Corporation | $60,801 | 0 |
| Statin, ezetimibe, and incident diabetes mellitus among US Veterans | Merck Sharp & Dohme Corporation | $50,019 | 0 |
| Assessment of cultural acceptability of long acting contraception in a diverse, urban population of young women. | Merck Sharp & Dohme Corporation | $39,546 | 0 |
| Mechanisms of CKD-induced Foam Cell Formation | Merck Sharp & Dohme Corporation | $23,994 | 0 |
| Carotid Plaque Composition by MRI during Lipid-lowering CPC | Merck Sharp & Dohme Corporation | $16,471 | 0 |
Top Doctors Receiving Payments for ZETIA
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $823,857
- Merck Sharp & Dohme LLC $108,453
Product Information
- Type Drug
- Total Payments $932,310
- Total Doctors 4
- Transactions 74
About ZETIA
ZETIA is a drug associated with $932,310 in payments to 4 healthcare providers, recorded across 74 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2024. In 2024, $108,453 was paid across 8 transactions to 0 doctors.
The most common payment nature for ZETIA is "Unspecified" ($932,264, 100.0% of total).
ZETIA is associated with 10 research studies, including "Treatment of unfavorable bleeding patterns in contraceptive implant users" ($326,714).